Evidence map›Paper›PMID 42742939›Full record

ArticleJAMA network open2026

E-Cigarette Directory Laws, Sales, and Product Availability From 3 Early-Adopting US States.

Fatma Romeh M Ali, Margaret Mahoney, Elizabeth L Seaman Jones, Michael A Tynan, Kristy Marynak

Abstract read
In one paragraph

Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fatma Romeh M AliCDC Foundation, Atlanta, Georgia.
Margaret MahoneyCDC Foundation, Atlanta, Georgia.
Elizabeth L Seaman JonesCDC Foundation, Atlanta, Georgia.
Michael A TynanCDC Foundation, Atlanta, Georgia.
Kristy MarynakCDC Foundation, Atlanta, Georgia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Flavored e-cigarettes are the most-used tobacco product among US youths and young adults. The US Food and Drug Administration (FDA) has authorized only 45 e-cigarette products, while thousands remain under review. Some states have enacted laws permitting sales of non-FDA-authorized products listed on state directories, but the impact of these laws is unknown. Objectives: To evaluate the association of directory laws with e-cigarette sales and product availability over time in Alabama, Oklahoma, and Louisiana, the first states to enact these laws. Design, Setting, and Participants: This cross-sectional study applied a synthetic difference-in-differences approach to assess state-level e-cigarette retail sales from the 4-week period ending January 31, 2021, through the 4-week period ending April 20, 2025. Alabama, Oklahoma, and Louisiana were compared with synthetic controls constructed from 31 states without directories, assessing changes before and after directory publication. Data were analyzed August 1, 2025, to July 20, 2026. Exposure: Implementation of directory laws. Main Outcomes and Measures: The primary outcome consisted of per capita e-cigarette nicotine sales, calculated as units sold × e-liquid volume × nicotine concentration, summed across products per state-month and divided by state population. Product availability was a secondary outcome, defined as the number of distinct products sold monthly in each state. Analyses were conducted overall and stratified by flavor and product type. Results: A total of 1904 state-month observations were included in the analysis. No associations of e-cigarette nicotine sales or product availability with directory listings were observed in Alabama or Oklahoma, where flavored disposables remained dominant. In Louisiana, the law was associated with a significant reduction in sales relative to synthetic controls (average treatment effect [ATT], -38.29% [95% CI, -53.10% to -18.80%). However, event-study analyses showed this decline was temporary, with the estimated treatment effect equal to -19.46% (95% CI, -27.32% to -10.76%) immediately after publication and reaching -63.43% (95% CI, -74.32% to -47.92%) in July 2024, 8 months after implementation. Sales then rebounded and the decrease became statistically nonsignificant by October 2024 as unlisted flavored disposables and menthol cartridges drove sales. In contrast, product availability in Louisiana declined persistently with an ATT of -53.55% (95% CI, -65.67% to -37.14%). In all states, more than half of sales were for unlisted products by the end of the study period. Conclusions and Relevance: In this cross-sectional study, directory laws in early-adopter states did not produce lasting declines in flavored e-cigarette sales. These findings suggest that directory laws instead might divert resources from evidence-based tobacco control strategies.

Indexed as

CommerceElectronic Nicotine Delivery SystemsAlabamaCross-Sectional StudiesHumansLouisianaOklahomaTobacco ControlUnited States

Identifiers

PMID42742939
PMCPMC13579438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.